Indivior Pharmaceuticals

INDV

Market cap $4.09B

Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript

Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.32 per share a year ago.

RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global Healthcare Conference – Miami, FL Joe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th.

RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST.

RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States.

Zacks highlights how Indivior, FIGS and Ulta Beauty delivered outsized gains as its ranks, recommendations and focus lists beat a volatile market.

Investors target stocks that have been on a bullish run. Stocks like INDV, AUGO, ERO and OI are seeing price strength, and the momentum is likely to continue.

Total Net Revenue Expected in the Range of $1,125 million to $1,195 million Total SUBLOCADE ®  Net Revenue Expected to be in the Range of $905 million to $945 million Non-GAAP Operating Expenses Expected in the Range of $430 million to $450 million Adjusted EBITDA Expected in the Range of $535 million to $575 million RICHMOND, Va., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) (“Indivior PLC” or the “Company”) today announced its full-year 2026 financial guidance.

Oregon-based Stonepine Capital Management reduced its Indivior stake by 250,000 shares in the third quarter. The overall position value fell by about $2.75 million from the previous period.